Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07346196 · ClinicalTrials.gov registry record · Phase 2
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
A Phase 2 study, sponsored by University of Chicago.
- Not yet
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07346196 is a Phase 2 study that has not yet begun recruiting, run by University of Chicago. The registered enrollment target is 90 participants.
The verdict
NCT07346196, a Phase 2 study, has not yet begun recruiting, sponsored by University of Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.
Interventions
- DRUG Carboplatin
- DRUG Cemiplimab
- DRUG Paclitaxel
- RADIATION Radiation
- DRUG Fianlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2027-02-07 |
| Est. Completion | 2031-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07346196
The ClinicalTrials.gov registry entry for NCT07346196 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT07346196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07346196 about?
NCT07346196 is a clinical study titled "A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck". The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.
What is the current status of trial NCT07346196?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2027-02-07. Estimated completion is 2031-08-22.
What interventions are being tested in trial NCT07346196?
The interventions under investigation include: Carboplatin (DRUG), Cemiplimab (DRUG), Paclitaxel (DRUG), Radiation (RADIATION), Fianlimab (DRUG).
Who is sponsoring clinical trial NCT07346196?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.